ATE323170T1 - Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. - Google Patents
Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann.Info
- Publication number
- ATE323170T1 ATE323170T1 AT98907032T AT98907032T ATE323170T1 AT E323170 T1 ATE323170 T1 AT E323170T1 AT 98907032 T AT98907032 T AT 98907032T AT 98907032 T AT98907032 T AT 98907032T AT E323170 T1 ATE323170 T1 AT E323170T1
- Authority
- AT
- Austria
- Prior art keywords
- express
- binding protein
- protein gene
- chemokine
- smallpox virus
- Prior art date
Links
- 101710172503 Chemokine-binding protein Proteins 0.000 title abstract 2
- 241000700647 Variola virus Species 0.000 title 1
- 101150045588 A38L gene Proteins 0.000 abstract 3
- 101150091700 A41L gene Proteins 0.000 abstract 3
- 101100107503 Vaccinia virus (strain Western Reserve) VACWR166 gene Proteins 0.000 abstract 3
- 102000019034 Chemokines Human genes 0.000 abstract 2
- 108010012236 Chemokines Proteins 0.000 abstract 2
- 241000700618 Vaccinia virus Species 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000027005 chemokine binding proteins Human genes 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9703592.7A GB9703592D0 (en) | 1997-02-21 | 1997-02-21 | Poxvirus chemokine-binding protein |
| GBGB9800113.4A GB9800113D0 (en) | 1998-01-05 | 1998-01-05 | A soluble vaccinia virus protein that binds chemokines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE323170T1 true ATE323170T1 (de) | 2006-04-15 |
Family
ID=26311039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98907032T ATE323170T1 (de) | 1997-02-21 | 1998-02-23 | Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US6355252B1 (enExample) |
| EP (2) | EP0985046B1 (enExample) |
| JP (1) | JP4191255B2 (enExample) |
| AT (1) | ATE323170T1 (enExample) |
| AU (1) | AU749921B2 (enExample) |
| DE (1) | DE69834179T2 (enExample) |
| WO (1) | WO1998037217A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69834179T2 (de) * | 1997-02-21 | 2007-02-01 | Oxxon Therapeutics Ltd. | Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. |
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| US20040241163A1 (en) * | 2001-04-05 | 2004-12-02 | Thomas Shenk | Compositions and methods for treating inflammation and related conditions |
| AU2002346056A1 (en) * | 2001-07-12 | 2003-01-29 | Immunex Corporation | Viral proteins capable of binding lar |
| GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| MXPA04002575A (es) * | 2001-09-20 | 2004-06-18 | Schering Corp | Quimiocinas como adyuventes de respuesta inmune. |
| AU2003259117A1 (en) * | 2002-07-10 | 2004-01-23 | The Regents Of The University Of California | Antimicrobial activity of interferon-inducible elr chemokines |
| AU2003258168B2 (en) * | 2002-08-12 | 2009-10-29 | Sillajen Biotherapeutics, Inc. | Methods and compositions concerning poxviruses and cancer |
| WO2005017208A1 (en) * | 2003-07-31 | 2005-02-24 | George Mason Intellectual Properties, Inc. | Compositions and methods for treating or preventing hiv infection |
| US20050175627A1 (en) * | 2003-09-24 | 2005-08-11 | Oxxon Therapeutics Ltd. | HIV pharmaccines |
| US20070160571A1 (en) * | 2006-01-11 | 2007-07-12 | Mitchell Krathwohl | Composition and method for inducing protective vaccine response |
| WO2006076383A2 (en) * | 2005-01-11 | 2006-07-20 | Rosetta Stone Labs, Llc | Composition and method for inducing a protective vaccine response |
| US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| EP1933857A2 (en) * | 2005-09-07 | 2008-06-25 | Jennerex Biotherapeutics ULC | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| EP1928916A2 (en) * | 2005-09-29 | 2008-06-11 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
| ES2354954T3 (es) | 2006-03-22 | 2011-03-21 | Viral Logic Systems Technology Corp. | Métodos para identificar dianas polipeptídicas. |
| US20110044945A1 (en) * | 2007-02-08 | 2011-02-24 | Rappaport Family Institute For Research In The Medical Sciences | Agents for the treatment of multiple sclerosis and methods of using same |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| WO2008149354A2 (en) | 2007-06-04 | 2008-12-11 | Rappaport Family Institute For Research In The Medical Sciences | Agents for the treatment of inflammatory diseases and methods of using same |
| WO2009082594A2 (en) | 2007-11-26 | 2009-07-02 | Fox Chase Cancer Center | Secreted/cell bound poxvirus proteins and methods of use thereof as vaccines and anti-viral agents |
| WO2010103517A1 (en) | 2009-03-12 | 2010-09-16 | Rappaport Family Institute For Research In The Medical Sciences | Soluble compositions for the treatment of cxcr3-ligand associated diseases |
| EP2477499B1 (en) | 2009-09-14 | 2018-04-11 | SillaJen Biotherapeutics, Inc. | Oncolytic vaccinia virus combination cancer therapy |
| CN103429258B (zh) | 2011-01-04 | 2016-03-09 | 新罗杰公司 | 通过施用溶瘤痘苗病毒生成针对肿瘤抗原的抗体和生成肿瘤特异性补体依赖性细胞毒性 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69628838T2 (de) | 1995-04-19 | 2004-05-06 | The John P. Robarts Research Institute, London | Chemokin bindendes protein und verfahren zu seiner verwendung |
| US6140064A (en) | 1996-09-10 | 2000-10-31 | Theodor-Kocher Institute | Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3 |
| DE69834179T2 (de) * | 1997-02-21 | 2007-02-01 | Oxxon Therapeutics Ltd. | Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. |
| WO1998036766A1 (en) * | 1997-02-21 | 1998-08-27 | Isis Innovation Limited | Anti-hiv protein |
| JP2001168323A (ja) * | 1999-12-06 | 2001-06-22 | Mitsubishi Electric Corp | 半導体装置の製造方法 |
-
1998
- 1998-02-23 DE DE69834179T patent/DE69834179T2/de not_active Expired - Fee Related
- 1998-02-23 AU AU63020/98A patent/AU749921B2/en not_active Ceased
- 1998-02-23 EP EP98907032A patent/EP0985046B1/en not_active Expired - Lifetime
- 1998-02-23 WO PCT/GB1998/000569 patent/WO1998037217A1/en not_active Ceased
- 1998-02-23 AT AT98907032T patent/ATE323170T1/de not_active IP Right Cessation
- 1998-02-23 EP EP20030022117 patent/EP1405916A1/en not_active Withdrawn
- 1998-02-23 JP JP53641598A patent/JP4191255B2/ja not_active Expired - Fee Related
- 1998-02-23 US US09/367,781 patent/US6355252B1/en not_active Expired - Fee Related
-
2002
- 2002-01-15 US US10/047,761 patent/US20020071849A1/en not_active Abandoned
-
2004
- 2004-02-18 US US10/781,262 patent/US7384643B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0985046B1 (en) | 2006-04-12 |
| JP2001513629A (ja) | 2001-09-04 |
| US20020071849A1 (en) | 2002-06-13 |
| US7384643B2 (en) | 2008-06-10 |
| DE69834179T2 (de) | 2007-02-01 |
| EP0985046A1 (en) | 2000-03-15 |
| US6355252B1 (en) | 2002-03-12 |
| DE69834179D1 (de) | 2006-05-24 |
| AU749921B2 (en) | 2002-07-04 |
| US20040142002A1 (en) | 2004-07-22 |
| JP4191255B2 (ja) | 2008-12-03 |
| EP1405916A1 (en) | 2004-04-07 |
| WO1998037217A1 (en) | 1998-08-27 |
| AU6302098A (en) | 1998-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE323170T1 (de) | Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. | |
| FI971613A7 (fi) | Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin | |
| FR2712603B1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
| FR2716893B1 (fr) | Virus recombinants, leur préparation et leur utilisation thérapeutique. | |
| DE3853088D1 (de) | Rekombinantes Avipoxvirus. | |
| FI951138A0 (fi) | Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa | |
| ATE328068T1 (de) | Papillomavirus vakzine | |
| KR970706806A (ko) | 신규한 아데노바이러스성 벡터, 패키징 세포주, 재조합 아데노바이러스와 그 방법(novel adenoviral vectors, packagning cell lines, recombinant adenoviruses and methods) | |
| ES2187527T3 (es) | Estructura de orden superior y enlace de acidos nucleicos peptidicos. | |
| ATE486614T1 (de) | Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie | |
| PT797676E (pt) | Vector adenoviral recombinante e metodos de utilizacao | |
| DE69032679D1 (de) | Threo (2R, 3S)-3-amino-2-hydroxypentansäure und threo (2R,3S)-3-(p-methoxy-benzyloxycarbonyl/FMOC) amino-2-hydroxy-pentansäure | |
| NZ219909A (en) | Recombinant vaccinia virus expressing human (hiv) retrovirus gene | |
| DE68921923D1 (de) | Rekombinante Coccidiosis-Vakzine. | |
| FI973309A0 (fi) | Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi | |
| FR2712602B1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
| AU4089899A (en) | Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy | |
| FR2724945B1 (fr) | Vecteurs viraux et utilisation en therapie genique | |
| EP0957936A4 (en) | COMPOSITIONS OF RECOMBINANT PAPILLOMAVIRUS VACCINES | |
| EP0227604A3 (en) | Use of oligopeptides in the treatment of viral infections | |
| FR2717495B1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
| FI971377L (fi) | Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geeniä: itsemurha- ja immuunistimuloiva geeni | |
| FR2717823B1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
| FR2717497B1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
| AU8132287A (en) | Recombinant vaccinia virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |